Retatrutide, by Soma Chems , is attracting considerable attention as a innovative therapy for obesity control . This unique compound integrates the mechanism of a GLP-1 receptor agonist and a GIP receptor agonist , designed to effectively promote metabolic improvements but also target related metabolic issues . Initial patient trials have indicated